Patient Resources

In The News

Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment

Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to his Rockville, MD, and Washington, DC area patients. Kybella is a non-surgical method to dissolve fat cells and is the first of its kind to be approved for the use of reducing moderate to severe fat deposits under the chin, commonly known as a double chin. Dr. Green participated in clinical trials for Kybella and has already treated many patients with success even though the treatment has only recently become generally available.

Kybella works by using an injectable treatment to dissolve fat cells and reshape the chin area without surgery. When injected into the submental fat area under the chin, Kybella destroys the localized deposits of fat cells. The key ingredient in Kybella is identical to deoxycholic acid, an acid naturally produced in the body.

“I’m thrilled that Kybella is now available to the general public,” says Dr. Lawrence Green, “I’m excited to offer the great results we saw in treating double chins during the clinical trials to more patients.”

Patients may receive up to 50 injections in a single treatment, and up to six single treatments administered no less than one month apart. Kybella is an ideal treatment option for patients with excess fat deposits that have been resistant to change with diet and exercise. Kybella is not designed to tighten loose, sagging, “turkey neck” type skin laxity. Side effects of Kybella may include numbness, nerve injury in the jaw area that can cause uneven smile, swelling, bruising, and pain at the injection site.

Dr. Green, a leading dermatologist, is frequently interviewed by national television networks, radio, and large circulation newspapers and magazines. Dr. Green is also recognized among medical professionals as a premier leader in injectable cosmetic treatments. He serves on the national faculty for the Radiesse wrinkle filler and is an original member for Kybella national physician trainers. Dr. Green also oversees a clinical trial center at his office, where patrons have the option to participate in clinical trials that offer the latest and most advanced treatments to help improve their skin.


Dr. Green Recommends Radiesse for Hand Augmentation to FDA

Dr. Green recommends Radiesse for Hand Augmentation to the FDA on behalf of the American Society for Dermatologic Surgery Association (ASDSA).

Dr. Green Discusses How Excess Weight May Contribute to Psoriasis

Dr. Green discusses weight and psoriasis in a Health Day article about the effects of weight loss on psoriasis.

Dr. Green Interviewed on WTOP About New Sunscreen Labels

Dr. Green discusses the broad-spectrum labeling in addition to SPF rating on sunscreens coming this summer in an interview on WTOP.

Dr. Green Interviewed for Health Central Article on Psoriasis

Dr. Green was recently interviewed for a story on the Top 5 Concerns for Women with Psoriasis.

Dr. Green Interviewed for CBS Local Affiliate WJZ Story

Dr. Green was interviewed for a story on the effects tanning beds can have on youth, and the efforts to ban their use. The story, featured on WJZ, can be found online.

Dr. Green Interviewed in US News Health Story on Psoriasis

Dr. Green was interviewed to discuss the additional burden that insurance difficulties can add to the lives of people with psoriasis.

Dr. Green Featured on WebMD Psoriasis Post

Dr. Green discusses treatment options for people with psoriasis in a featured article on WebMD.

Dr. Green discusses the dangers of tanning

Dr. Green is interviewed on healthcentral.com to discuss the dangers of tanning in light of a recent ban of tanning beds for minors in California.

Dr. Green Discusses How Excess Weight May Contribute to Psoriasis

Dr. Green discusses weight and psoriasis in a Health Day article about the effects of weight loss on psoriasis.

Dr. Green Publishes in Journal of Drugs in Dermatologyjdd

The article appearing in the May 2010 issue involves the treatment of Acne Vulgaris
This 16-week study evaluated once-daily tazarotene 0.1% cream and adapalene 0.3% gel in patients with moderate-to-severe acne. Patients treated with tazarotene 0.1% cream performed better in many acne efficacy measures (reduction in lesion counts, percentage of patients achieving a 50 percent lesion count reduction, overall disease severity, investigators’ global assessment) than did patients treated with adapalene 0.3% gel.

Dr. Green is an Acne.com featured dermatologist!

Featured in articles on Acne.com, Dr. Green gives advice on the best way to maximize results from your acne treatments, and more.


External Content Disclaimer

*Please note that pages of this site may be linked to other websites, which may have different terms of use and privacy practices than Privia Medical Group. Privia does not own, control, manage, supervise, direct, or otherwise have involvement in such other websites or the content of such websites. Privia is not responsible for the content of any linked websites. Privia is not acting as an agent for these websites, nor does Privia endorse or guarantee, in any way, their websites, content, or products. Privia makes no representation or warranty regarding the accuracy of information contained in linked websites, takes no responsibility for the use of copyrighted or otherwise protected materials on such linked websites, and has no control over the privacy practices or use of user information at such linked websites.